Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Efficacy of bergamot: From anti-inflammatory and anti-oxidative mechanisms to clinical applications as preventive agent for cardiovascular morbidity, skin diseases, and mood alterations.

Perna S, Spadaccini D, Botteri L, Girometta C, Riva A, Allegrini P, Petrangolini G, Infantino V, Rondanelli M.

Food Sci Nutr. 2019 Jan 25;7(2):369-384. doi: 10.1002/fsn3.903. eCollection 2019 Feb. Review.

2.

Hypoglycemic and Hypolipemic Effects of a New Lecithin Formulation of Bergamot Polyphenolic Fraction: A Double Blind, Randomized, Placebo- Controlled Study.

Mollace V, Scicchitano M, Paone S, Casale F, Calandruccio C, Gliozzi M, Musolino V, Carresi C, Maiuolo J, Nucera S, Riva A, Allegrini P, Ronchi M, Petrangolini G, Bombardelli E.

Endocr Metab Immune Disord Drug Targets. 2019;19(2):136-143. doi: 10.2174/1871530319666181203151513.

PMID:
30501605
3.

Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin.

Riva A, Ronchi M, Petrangolini G, Bosisio S, Allegrini P.

Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):169-177. doi: 10.1007/s13318-018-0517-3.

4.

A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Macis D, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2017 Jun;10(6):363-370. doi: 10.1158/1940-6207.CAPR-16-0298. Epub 2017 Apr 11.

5.

A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Puccio A, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2016 Jan;9(1):89-95. doi: 10.1158/1940-6207.CAPR-15-0123. Epub 2015 Nov 2.

6.

Protective effect of Panax ginseng in cisplatin-induced cachexia in rats.

Lobina C, Carai MA, Loi B, Gessa GL, Riva A, Cabri W, Petrangolini G, Morazzoni P, Colombo G.

Future Oncol. 2014 May;10(7):1203-14. doi: 10.2217/fon.13.276.

PMID:
24947261
7.

Effect of SAMITAL® in the treatment of chemotherapy-induced mucositis in adult oncohematological patients.

Bertoglio JC, Calderón S, Lesina B, Pilleux L, Morazzoni P, Riva A, Bombardelli E, Ronchi M, Cabri W, Petrangolini G.

Future Oncol. 2013 Nov;9(11):1727-32. doi: 10.2217/fon.13.164.

PMID:
24156332
8.

SAMITAL®: a new botanical drug for the treatment of mucositis induced by oncological therapies.

Morazzoni P, Petrangolini G, Bombardelli E, Ronchi M, Cabri W, Riva A.

Future Oncol. 2013 Nov;9(11):1717-25. doi: 10.2217/fon.13.165. Review.

PMID:
24156331
9.

Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E, Zaffaroni N, Pisano C, Penco S, Vlodavsky I, Zunino F.

Biochem Pharmacol. 2013 May 15;85(10):1424-32. doi: 10.1016/j.bcp.2013.02.023. Epub 2013 Mar 1.

PMID:
23466421
10.

Management of gastrointestinal mucositis due to cancer therapies in pediatric patients: results of a case series with SAMITAL(®).

Bertoglio JC, Folatre I, Bombardelli E, Riva A, Morazzoni P, Ronchi M, Petrangolini G.

Future Oncol. 2012 Nov;8(11):1481-6. doi: 10.2217/fon.12.132.

PMID:
23148620
11.

SAMITAL® improves chemo/radiotherapy-induced oral mucositis in patients with head and neck cancer: results of a randomized, placebo-controlled, single-blind Phase II study.

Pawar D, Neve RS, Kalgane S, Riva A, Bombardelli E, Ronchi M, Petrangolini G, Morazzoni P.

Support Care Cancer. 2013 Mar;21(3):827-34. doi: 10.1007/s00520-012-1586-5. Epub 2012 Sep 4.

PMID:
22945882
12.

The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.

Cassinelli G, Zuco V, Petrangolini G, De Cesare M, Tortoreto M, Lanzi C, Cominetti D, Zaffaroni N, Orlandi A, Passeri D, Meco D, Di Francesco AM, Riccardi R, Bucci F, Pisano C, Zunino F.

Biochem Pharmacol. 2012 Jul 15;84(2):163-71. doi: 10.1016/j.bcp.2012.04.005. Epub 2012 Apr 13.

PMID:
22525722
13.

Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.

Nicolini V, Cassinelli G, Cuccuru G, Bongarzone I, Petrangolini G, Tortoreto M, Mondellini P, Casalini P, Favini E, Zaffaroni N, Zunino F, Lanzi C.

Biochem Pharmacol. 2011 Oct 1;82(7):778-88. doi: 10.1016/j.bcp.2011.06.037. Epub 2011 Jul 2.

PMID:
21741956
14.

Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.

Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, Perego P, Zuco V, Orlandi A, Passeri D, Carminati P, Cavazza C, Zunino F.

Clin Cancer Res. 2010 Aug 1;16(15):3944-53. doi: 10.1158/1078-0432.CCR-10-0964. Epub 2010 Jun 18.

15.

In vivo effects of rosiglitazone in a human neuroblastoma xenograft.

Cellai I, Petrangolini G, Tortoreto M, Pratesi G, Luciani P, Deledda C, Benvenuti S, Ricordati C, Gelmini S, Ceni E, Galli A, Balzi M, Faraoni P, Serio M, Peri A.

Br J Cancer. 2010 Feb 16;102(4):685-92. doi: 10.1038/sj.bjc.6605506. Epub 2010 Jan 12.

16.

Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu.

Pratesi G, Petrangolini G, Tortoreto M, Addis A, Zunino F, Calcaterra C, Merlo A, Tagliabue E, Menard S, Balsari A.

J Immunother. 2008 Jul-Aug;31(6):537-44. doi: 10.1097/CJI.0b013e31817c37ff.

PMID:
18528301
17.

Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft.

Petrangolini G, Tortoreto M, Perego P, Carenini N, De Cesare M, Balsari A, Zunino F, Pratesi G.

Cancer Biol Ther. 2008 Apr;7(4):596-601. Epub 2008 Jan 9.

PMID:
18364568
18.

Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies.

Supino R, Petrangolini G, Pratesi G, Tortoreto M, Favini E, Bo LD, Casalini P, Radaelli E, Croce AC, Bottiroli G, Misiano P, Farina C, Zunino F.

J Pharmacol Exp Ther. 2008 Jan;324(1):15-22. Epub 2007 Oct 1.

PMID:
17909082
19.

Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring.

Beretta GL, Petrangolini G, De Cesare M, Pratesi G, Perego P, Tinelli S, Tortoreto M, Zucchetti M, Frapolli R, Bello E, Manzotti C, Fontana G, Bombardelli E, Battaglia A, Samorì C, Zunino F.

Cancer Res. 2006 Nov 15;66(22):10976-82.

20.

Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1.

Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, Poletti A, Zunino F.

Mol Cancer Ther. 2006 Sep;5(9):2388-97.

21.

Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.

Petrangolini G, Cuccuru G, Lanzi C, Tortoreto M, Belluco S, Pratesi G, Cassinelli G, Zunino F.

Biochem Pharmacol. 2006 Aug 14;72(4):405-14. Epub 2006 Jun 6.

PMID:
16756963
22.

Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.

Petrangolini G, Supino R, Pratesi G, Dal Bo L, Tortoreto M, Croce AC, Misiano P, Belfiore P, Farina C, Zunino F.

J Pharmacol Exp Ther. 2006 Sep;318(3):939-46. Epub 2006 May 19.

PMID:
16714402
23.

Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas.

Pradilla G, Legnani FG, Petrangolini G, Francescato P, Chillemi F, Tyler BM, Gaini SM, Brem H, Olivi A, DiMeco F.

Neurosurgery. 2005 Nov;57(5):1032-40; discussion 1032-40.

24.

Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.

Pratesi G, Petrangolini G, Tortoreto M, Addis A, Belluco S, Rossini A, Selleri S, Rumio C, Menard S, Balsari A.

Cancer Res. 2005 Jul 15;65(14):6388-93.

25.

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG.

Cancer Res. 2005 Jul 1;65(13):5506-11.

26.

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F.

J Natl Cancer Inst. 2004 Jul 7;96(13):1006-14.

PMID:
15240784
27.

Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.

Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, Ménard S, Pratesi G.

Eur J Cancer. 2004 May;40(8):1275-81.

PMID:
15110894
28.

Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.

Petrangolini G, Cassinelli G, Pratesi G, Tortoreto M, Favini E, Supino R, Lanzi C, Belluco S, Zunino F.

Br J Cancer. 2004 Apr 5;90(7):1464-8.

29.

Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.

Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, Giordano V, Laccabue D, Lanzi C, Zunino F.

Mol Cancer Res. 2003 Oct;1(12):863-70.

Supplemental Content

Loading ...
Support Center